Evolus Statistics
Total Valuation
Evolus has a market cap or net worth of $433.32 million. The enterprise value is $548.44 million.
Important Dates
The last earnings date was Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolus has 65.85 million shares outstanding. The number of shares has increased by 2.53% in one year.
| Current Share Class | 65.85M |
| Shares Outstanding | 65.85M |
| Shares Change (YoY) | +2.53% |
| Shares Change (QoQ) | -0.25% |
| Owned by Insiders (%) | 11.08% |
| Owned by Institutions (%) | 65.33% |
| Float | 50.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.44 |
| Forward PS | 1.26 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.04
| Current Ratio | 2.04 |
| Quick Ratio | 1.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.06% |
| Return on Invested Capital (ROIC) | -15.13% |
| Return on Capital Employed (ROCE) | -20.60% |
| Weighted Average Cost of Capital (WACC) | 10.75% |
| Revenue Per Employee | $862,260 |
| Profits Per Employee | -$124,066 |
| Employee Count | 350 |
| Asset Turnover | 1.39 |
| Inventory Turnover | 5.88 |
Taxes
In the past 12 months, Evolus has paid $861,000 in taxes.
| Income Tax | 861,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.04% in the last 52 weeks. The beta is 1.29, so Evolus's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -35.04% |
| 50-Day Moving Average | 5.05 |
| 200-Day Moving Average | 6.01 |
| Relative Strength Index (RSI) | 73.77 |
| Average Volume (20 Days) | 1,016,322 |
Short Selling Information
The latest short interest is 6.62 million, so 10.05% of the outstanding shares have been sold short.
| Short Interest | 6.62M |
| Short Previous Month | 6.52M |
| Short % of Shares Out | 10.05% |
| Short % of Float | 13.08% |
| Short Ratio (days to cover) | 7.68 |
Income Statement
In the last 12 months, Evolus had revenue of $301.79 million and -$43.42 million in losses. Loss per share was -$0.67.
| Revenue | 301.79M |
| Gross Profit | 199.35M |
| Operating Income | -31.44M |
| Pretax Income | -42.56M |
| Net Income | -43.42M |
| EBITDA | -23.15M |
| EBIT | -31.44M |
| Loss Per Share | -$0.67 |
Full Income StatementBalance Sheet
The company has $49.79 million in cash and $164.90 million in debt, with a net cash position of -$115.11 million or -$1.75 per share.
| Cash & Cash Equivalents | 49.79M |
| Total Debt | 164.90M |
| Net Cash | -115.11M |
| Net Cash Per Share | -$1.75 |
| Equity (Book Value) | -28.78M |
| Book Value Per Share | -0.44 |
| Working Capital | 70.90M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$36.59 million and capital expenditures -$3.54 million, giving a free cash flow of -$40.12 million.
| Operating Cash Flow | -36.59M |
| Capital Expenditures | -3.54M |
| Depreciation & Amortization | 8.29M |
| Net Borrowing | 34.98M |
| Free Cash Flow | -40.12M |
| FCF Per Share | -$0.61 |
Full Cash Flow StatementMargins
Gross margin is 66.06%, with operating and profit margins of -10.42% and -14.39%.
| Gross Margin | 66.06% |
| Operating Margin | -10.42% |
| Pretax Margin | -14.10% |
| Profit Margin | -14.39% |
| EBITDA Margin | -7.67% |
| EBIT Margin | -10.42% |
| FCF Margin | n/a |
Dividends & Yields
Evolus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.53% |
| Shareholder Yield | -2.53% |
| Earnings Yield | -10.02% |
| FCF Yield | -9.26% |
Analyst Forecast
The average price target for Evolus is $15.50, which is 135.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 135.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 17.37% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolus has an Altman Z-Score of -1.83 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.83 |
| Piotroski F-Score | 2 |
